Study to Evaluate an Oxaliplatin-based Chemotherapy in Patients With Resistant or Relapsing Non-Hodgkin Lymphoma.

Status

UNKNOWN

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01019863

Acronym

LNH-RGDOX

Enrollment

Registered

2009-11-25

Start date

2008-10-31

Completion date

2011-10-31

Last updated

2011-01-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-Hodgkin Lymphoma

Brief summary

Evaluation of the efficacy, tolerance, quality of life and cost effectiveness of the association of Oxaliplatin, Gemcitabine, Rituximab and Dexamethasone for treatment of patients with refractory or relapsing non-Hodgkin lymphoma.

Interventions

DRUGoxaliplatin

oxaliplatin 100mg/m2 + Rituxan 375 mg/m2 + Gemcitabine 1000mg/m2 every 2 weeks for 8 cycles

Study design

Allocation

NON_RANDOMIZED

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

1. Patients 18 years or above at the time of inclusion. 2. Documented CD20+ NHL, refractory or relapsing after first line chemotherapy. 3. No contraindication to Oxaliplatin, Gemcitabine, Dexamethasone or Rituximab.

Exclusion criteria

1. Other types of non-Hodgkin lymphoma 2. Pregnancy and lactation. 3. Patient unable to give written informed consent. 4. Contra-indication ou intolerance to any of the components of the RGDOx chemotherapy.

Design outcomes

Primary

Measure	Time frame
Response rate to RGDOx in patients with relapsing or refractory NHL	Within 3 months after chemotherapy (6-8 cycles)

Countries

Canada

Contacts

Primary ContactAnick Champoux, RN

achampoux.chus@ssss.gouv.qc.ca819-346-1110

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 8, 2026